SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is trending as investors digest Q3 earnings, updates to 2025 guidance, and the impact of a supplier fire. Community members are weighing the effects of tariff relief and production adjustments, with some expressing optimism about the F-150 truck outlook and others debating the company's EV strategy and long-term potential.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

Grayscale Bitcoin Mini Trust ETF ($BTC) is trending amid Bitcoin's climb toward all-time highs and increasing discussion of potential market manipulation. Community members are weighing in on technical analyses, potential price targets, and the impact of broader market forces. There is also discussion of possible rotation into BTC from other assets.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

Deckers Outdoor Corp. is trending due to recent earnings and updated ratings, sparking debate about its valuation and future performance. While some analysts highlight the company's strong brands and growth potential, others express concerns about slowing sales and the impact of tariffs. The community is actively discussing potential catalysts, short-term bounce opportunities, and the possibility of a buyback program influencing the stock's direction.

$BALLIN is the perfect meme for everyone showing up every single day.  To be BALLIN, you gotta B-All-In.  The meaning to B All In doesn't only apply to the funds you invest.  It's about dedication.   The countless hours of research.   The endless raiding and working for your bags.  Not knowing how to quit while everyone is telling you you're wrong.  It's about believing in something.  Keep $BALLIN

B All In

$BALLIN is gaining attention, with community members emphasizing its potential for significant gains and associating it with a luxury lifestyle. The token, available on Phantom Wallet, is being touted for its strong chart and 'championship energy,' though some caution against the hype. Discussions frequently mention related cryptocurrencies like $SOL, $BTC, and $PEPE.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

Recursion Pharmaceuticals Inc

RXRX is trending due to community discussion around its high short interest and potential for a squeeze, further fueled by NVIDIA's investment and a presentation at the GITEX Global conference in Dubai. Some anticipate news or catalysts that could trigger a significant upward move. Bullish sentiment also stems from potential expansion in the Middle East and the broader AI-driven healthcare narrative.

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Inhibrx Biosciences Inc.

Inhibrx Inc

INBX is trending due to positive news regarding a potential accelerated approval pathway for its INBRX-101 drug, leading to a significant gap up. The community is closely watching price movements and Fibonacci extension levels while analysts are raising price targets, creating a mix of bullish sentiment and skepticism about FDA approval. The stock is exhibiting high volatility as traders weigh the potential for further gains against concerns of a possible offering.

Imperial Petroleum, Inc. is a ship-owning company, which engages in providing petroleum products and crude oil seaborne transportation services. It offers international seaborne transportation services to oil producers, refineries, and commodities traders. It has a fleet of three medium range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil and jet fuel, as well as edible oils and chemicals, and one Aframax tanker which is used for carrying crude oil. The company was founded on May 14, 2021 and is headquartered in Athens, Greece.

Imperial Petroleum Inc

IMPP is trending due to community speculation about potential catalysts, including a possible buyback program or positive news related to its fleet expansion. Discussions revolve around the company's financial health, especially its cash reserves, and its potential to benefit from rising oil prices and geopolitical tensions. Some investors express frustration with the company's management and share price performance, while others remain hopeful for a turnaround.

Picard Medical, Inc. is a medical technology company, which manufactures and sells the only U.S. FDA, and Health Canada approved implantable SynCardia TAH. It develops the first fully implantable SynCardia TAH as an alternative to heart transplantation for patients with biventricular heart failure in the U.S. and around the world. The company is headquartered in Tucson, AZ.

Picard Medical Inc.

Picard Medical (PMI) is trending amid mixed sentiments following its IPO, with community members discussing the company's financials and debating its long-term potential. Some traders are pointing to potential pump and dump schemes, while others focus on the artificial heart technology and potential buyout. The community is closely watching the stock's price action and volatility.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

GALT is trending as investors discuss its potential buyout, particularly awaiting developments from the AASLD meeting in November and a possible FDA meeting before year-end. Community talking points include speculation around share lending, short squeezes, and the potential for a buyout offer with significant ROI. The discussion also involves positive trial data and potential partnerships in the liver disease treatment space.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending as investors discuss the potential impact of IBM's quantum computing algorithm on AMD chips, sparking speculation about the Xilinx acquisition and future growth in AI and quantum computing. Bullish sentiment is fueled by the anticipation of upcoming earnings and potential new highs, while others remain cautious due to broader market concerns and profit-taking opportunities. The community is actively debating AMD's valuation and potential partnerships, especially in relation to AI and data centers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are You Looking for a Top Momentum Pick? Why Opus Genetics, Inc. (IRD) is a Great Choice

Does Opus Genetics, Inc. (IRD) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks.com featured highlights include Sally Beauty, Broadstone Net Lease and Opus Genetics

Sally Beauty, Broadstone Net Lease, and Opus Genetics make Zacks' "Under $20 Breakout Trio" list for investors eyeing growth.

The Under $20 Breakout Trio Investors Shouldn't Ignore 

Sally Beauty, Broadstone Net Lease and Opus Genetics emerge as today's breakout stock picks under $20, flagged for potential near-term gains. 

Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates

Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of +52.00% and -12.13%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates

Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of +51.61% and +118.09%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock?

Vir Biotechnology (VIR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates

Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates

Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates

Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates

Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Durham, NC.

Current Price	$2.00
Prev Close	$1.95
Open	$1.98
Dividend Yield	0.00%
50-Day Moving Average	$1.57
Beta	1.00
Avg. Volume	369,419.29
PE Ratio	-1.14

52-Week High	$2.16
52-Week Low	$0.65
Market Capitalization	$119.82M
EPS (Annual)	-$2.15
Price to Book	6.86
Revenue Per Employee	$610,666.67
Enterprise Value/EBITDA	N/A

IRD
Opus Genetics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IRD News

IRDOpus Genetics Inc.